Summary

The global preclinical imaging market is projected to witness steady growth as pharmaceutical, biotechnology, academic, and contract research organizations increasingly adopt advanced imaging technologies to support early-stage research. The market is valued at US$1.1 Bn in 2026 and is expected to reach US$1.7 Bn by 2033, expanding at a CAGR of 6.10% during the forecast period. Preclinical imaging has become an essential tool in drug discovery, disease modeling, toxicology assessment, biomarker validation, and translational research, enabling researchers to visualize biological processes in living subjects with improved accuracy and efficiency.

Preclinical imaging technologies help reduce uncertainty in early research by allowing non-invasive, real-time evaluation of anatomical, molecular, and functional changes. As the demand for faster drug development, precision medicine, and improved research productivity rises, the market is gaining momentum across laboratories, research institutes, and life sciences companies.

Market Insights

Preclinical imaging plays a critical role in bridging laboratory research and clinical development. It supports the evaluation of drug candidates before human trials, helping researchers assess safety, efficacy, biodistribution, disease progression, and treatment response. Modalities such as MRI, PET, SPECT, CT, optical imaging, ultrasound, and multimodal systems are widely used to generate detailed insights into biological mechanisms.

The growing complexity of therapeutic research, especially in oncology, neurology, cardiovascular diseases, metabolic disorders, and infectious diseases, is increasing the need for high-resolution and quantitative imaging solutions. Researchers are also using imaging agents and reagents to improve visualization of cellular and molecular activity, supporting more accurate interpretation of preclinical outcomes.

The market is also benefiting from increasing use of integrated imaging platforms that combine multiple modalities. These systems allow researchers to capture complementary data from the same subject, improving study quality while reducing animal usage and research timelines. As regulatory expectations for robust preclinical evidence increase, imaging-based studies are becoming more important in early development pipelines.

Drivers

One of the major drivers of the preclinical imaging market is the rising investment in drug discovery and development. Pharmaceutical and biotechnology companies are under pressure to improve success rates, reduce late-stage failures, and accelerate time-to-market. Preclinical imaging supports these goals by providing early, visual, and measurable evidence of drug activity and safety.

The increasing prevalence of chronic and complex diseases is also driving market demand. Researchers require advanced tools to understand disease mechanisms, test novel therapies, and validate biomarkers. Preclinical imaging enables longitudinal studies, allowing repeated monitoring of the same subject over time. This reduces variability and provides deeper insight into treatment effects.

Another key growth factor is the expansion of translational research. Academic institutions and research organizations are increasingly focused on moving discoveries from laboratory settings toward clinical application. Imaging technologies support this transition by generating data that can be aligned with clinical imaging methods, improving the relevance of preclinical findings.

Technological advancements are further strengthening market growth. Improvements in image resolution, sensitivity, software analytics, automation, and hybrid imaging platforms are making preclinical studies more accurate and efficient. The integration of artificial intelligence and advanced image analysis tools is also helping researchers manage large datasets and extract meaningful insights faster.

Business Opportunity

The preclinical imaging market presents strong opportunities for manufacturers, service providers, reagent suppliers, and research technology companies. Demand is increasing for compact, high-performance, and user-friendly imaging systems that can serve diverse research applications. Companies offering multimodal platforms, advanced software, and specialized imaging reagents are well positioned to benefit from market expansion.

Contract research organizations are emerging as an important customer group as pharmaceutical and biotech companies outsource preclinical studies to reduce infrastructure costs and improve operational flexibility. This creates opportunities for imaging service providers that can deliver validated, high-quality imaging studies across multiple disease areas.

There is also growing opportunity in personalized medicine and targeted therapy development. As researchers focus on therapies designed for specific molecular pathways, preclinical imaging is becoming essential for tracking drug behavior, target engagement, and biomarker expression. Imaging agent validation is expected to remain an important application area as new diagnostic and therapeutic approaches advance.

Small and mid-sized biotech companies are also contributing to demand. Many of these firms require access to advanced imaging capabilities but may not invest directly in expensive infrastructure. This trend supports growth in shared imaging facilities, academic-industry partnerships, and outsourced imaging services.

Region Analysis

North America is expected to remain a leading region in the preclinical imaging market, supported by strong pharmaceutical research activity, advanced healthcare infrastructure, major academic research centers, and high adoption of innovative imaging technologies. The presence of established life sciences companies and contract research organizations further supports regional growth.

Europe is also a significant market, driven by strong biomedical research programs, government-supported innovation, and growing investment in translational medicine. Countries across the region are adopting advanced imaging tools to support drug development, disease research, and academic studies.

Asia Pacific is expected to record growing demand during the forecast period as pharmaceutical manufacturing, biotechnology research, and academic life sciences programs expand across countries such as China, India, Japan, and South Korea. Rising R&D investments, improving laboratory infrastructure, and increasing outsourcing activity are supporting regional market development.

Latin America and the Middle East & Africa are gradually adopting preclinical imaging technologies as research capabilities improve. Although these regions currently represent smaller shares, expanding healthcare research investments and partnerships with global institutions may create future growth opportunities.

Key Players

The preclinical imaging market includes several companies focused on imaging systems, reagents, research tools, and related services. Key players include:

• Bruker Corporation

• Cubresa Inc.

• Siemens Healthineers

• Revvity, formerly PerkinElmer, Inc.

• MR Solutions

• Mediso Ltd.

• Rigaku, including MILabs B.V.

• Aspect Imaging

• TriFoil Imaging

• FUJIFILM VisualSonics

• Nikon Instruments Inc.

• Molecular Devices, LLC

• BioVet Solutions

• Inviscan SAS

These companies are focusing on product innovation, imaging performance, software capabilities, partnerships, and application-specific solutions to strengthen their market presence. Competition is shaped by technology quality, modality range, service support, image analysis capabilities, and the ability to meet evolving research needs.

Segmentation

By Product Type

• Modality

• Reagent

• Service

By Application

• Drug Discovery & Development

• Toxicology & Pharmacokinetics Studies

• Basic & Translational Research

• Disease Mechanism & Pathophysiology Studies

• Biomarker & Imaging Agent Validation

• Others

By End-User

• Pharma and Biotech Companies

• Contract Research Organizations, CROs

• Academic and Research Institutes

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Preclinical Imaging Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Preclinical Imaging Market Outlook, 2020 - 2033
3.1. Global Preclinical Imaging Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
3.1.1. Modality
3.1.2. Reagent
3.1.3. Reagent
3.2. Global Preclinical Imaging Market Outlook, by Application, Value (US$ Bn), 2020-2033
3.2.1. Drug Discovery & Development
3.2.2. Toxicology & Pharmacokinetics Studies
3.2.3. Basic & Translational Research
3.2.4. Basic & Translational Research
3.2.5. Biomarker & Imaging Agent Validation
3.2.6. Others
3.3. Global Preclinical Imaging Market Outlook, by End-User, Value (US$ Bn), 2020-2033
3.3.1. Pharma and Biotech Companies
3.3.2. Contract Research Organizations (CROs)
3.3.3. Academic and Research Institutes
3.3.4. Others
3.4. Global Preclinical Imaging Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.4.1. North America
3.4.2. Europe
3.4.3. Asia Pacific
3.4.4. Latin America
3.4.5. Middle East & Africa
4. North America Preclinical Imaging Market Outlook, 2020 - 2033
4.1. North America Preclinical Imaging Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
4.1.1. Modality
4.1.2. Reagent
4.1.3. Reagent
4.2. North America Preclinical Imaging Market Outlook, by Application, Value (US$ Bn), 2020-2033
4.2.1. Drug Discovery & Development
4.2.2. Toxicology & Pharmacokinetics Studies
4.2.3. Basic & Translational Research
4.2.4. Basic & Translational Research
4.2.5. Biomarker & Imaging Agent Validation
4.2.6. Others
4.3. North America Preclinical Imaging Market Outlook, by End-User, Value (US$ Bn), 2020-2033
4.3.1. Pharma and Biotech Companies
4.3.2. Contract Research Organizations (CROs)
4.3.3. Academic and Research Institutes
4.3.4. Others
4.4. North America Preclinical Imaging Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.4.1. U.S. Preclinical Imaging Market Outlook, by Product Type, 2020-2033
4.4.2. U.S. Preclinical Imaging Market Outlook, by Application, 2020-2033
4.4.3. U.S. Preclinical Imaging Market Outlook, by End-User, 2020-2033
4.4.4. Canada Preclinical Imaging Market Outlook, by Product Type, 2020-2033
4.4.5. Canada Preclinical Imaging Market Outlook, by Application, 2020-2033
4.4.6. Canada Preclinical Imaging Market Outlook, by End-User, 2020-2033
4.5. BPS Analysis/Market Attractiveness Analysis
5. Europe Preclinical Imaging Market Outlook, 2020 - 2033
5.1. Europe Preclinical Imaging Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
5.1.1. Modality
5.1.2. Reagent
5.1.3. Reagent
5.2. Europe Preclinical Imaging Market Outlook, by Application, Value (US$ Bn), 2020-2033
5.2.1. Drug Discovery & Development
5.2.2. Toxicology & Pharmacokinetics Studies
5.2.3. Basic & Translational Research
5.2.4. Basic & Translational Research
5.2.5. Biomarker & Imaging Agent Validation
5.2.6. Others
5.3. Europe Preclinical Imaging Market Outlook, by End-User, Value (US$ Bn), 2020-2033
5.3.1. Pharma and Biotech Companies
5.3.2. Contract Research Organizations (CROs)
5.3.3. Academic and Research Institutes
5.3.4. Others
5.4. Europe Preclinical Imaging Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.4.1. Germany Preclinical Imaging Market Outlook, by Product Type, 2020-2033
5.4.2. Germany Preclinical Imaging Market Outlook, by Application, 2020-2033
5.4.3. Germany Preclinical Imaging Market Outlook, by End-User, 2020-2033
5.4.4. Italy Preclinical Imaging Market Outlook, by Product Type, 2020-2033
5.4.5. Italy Preclinical Imaging Market Outlook, by Application, 2020-2033
5.4.6. Italy Preclinical Imaging Market Outlook, by End-User, 2020-2033
5.4.7. France Preclinical Imaging Market Outlook, by Product Type, 2020-2033
5.4.8. France Preclinical Imaging Market Outlook, by Application, 2020-2033
5.4.9. France Preclinical Imaging Market Outlook, by End-User, 2020-2033
5.4.10. U.K. Preclinical Imaging Market Outlook, by Product Type, 2020-2033
5.4.11. U.K. Preclinical Imaging Market Outlook, by Application, 2020-2033
5.4.12. U.K. Preclinical Imaging Market Outlook, by End-User, 2020-2033
5.4.13. Spain Preclinical Imaging Market Outlook, by Product Type, 2020-2033
5.4.14. Spain Preclinical Imaging Market Outlook, by Application, 2020-2033
5.4.15. Spain Preclinical Imaging Market Outlook, by End-User, 2020-2033
5.4.16. Russia Preclinical Imaging Market Outlook, by Product Type, 2020-2033
5.4.17. Russia Preclinical Imaging Market Outlook, by Application, 2020-2033
5.4.18. Russia Preclinical Imaging Market Outlook, by End-User, 2020-2033
5.4.19. Rest of Europe Preclinical Imaging Market Outlook, by Product Type, 2020-2033
5.4.20. Rest of Europe Preclinical Imaging Market Outlook, by Application, 2020-2033
5.4.21. Rest of Europe Preclinical Imaging Market Outlook, by End-User, 2020-2033
5.5. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Preclinical Imaging Market Outlook, 2020 - 2033
6.1. Asia Pacific Preclinical Imaging Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
6.1.1. Modality
6.1.2. Reagent
6.1.3. Reagent
6.2. Asia Pacific Preclinical Imaging Market Outlook, by Application, Value (US$ Bn), 2020-2033
6.2.1. Drug Discovery & Development
6.2.2. Toxicology & Pharmacokinetics Studies
6.2.3. Basic & Translational Research
6.2.4. Basic & Translational Research
6.2.5. Biomarker & Imaging Agent Validation
6.2.6. Others
6.3. Asia Pacific Preclinical Imaging Market Outlook, by End-User, Value (US$ Bn), 2020-2033
6.3.1. Pharma and Biotech Companies
6.3.2. Contract Research Organizations (CROs)
6.3.3. Academic and Research Institutes
6.3.4. Others
6.4. Asia Pacific Preclinical Imaging Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.4.1. China Preclinical Imaging Market Outlook, by Product Type, 2020-2033
6.4.2. China Preclinical Imaging Market Outlook, by Application, 2020-2033
6.4.3. China Preclinical Imaging Market Outlook, by End-User, 2020-2033
6.4.4. Japan Preclinical Imaging Market Outlook, by Product Type, 2020-2033
6.4.5. Japan Preclinical Imaging Market Outlook, by Application, 2020-2033
6.4.6. Japan Preclinical Imaging Market Outlook, by End-User, 2020-2033
6.4.7. South Korea Preclinical Imaging Market Outlook, by Product Type, 2020-2033
6.4.8. South Korea Preclinical Imaging Market Outlook, by Application, 2020-2033
6.4.9. South Korea Preclinical Imaging Market Outlook, by End-User, 2020-2033
6.4.10. India Preclinical Imaging Market Outlook, by Product Type, 2020-2033
6.4.11. India Preclinical Imaging Market Outlook, by Application, 2020-2033
6.4.12. India Preclinical Imaging Market Outlook, by End-User, 2020-2033
6.4.13. Southeast Asia Preclinical Imaging Market Outlook, by Product Type, 2020-2033
6.4.14. Southeast Asia Preclinical Imaging Market Outlook, by Application, 2020-2033
6.4.15. Southeast Asia Preclinical Imaging Market Outlook, by End-User, 2020-2033
6.4.16. Rest of SAO Preclinical Imaging Market Outlook, by Product Type, 2020-2033
6.4.17. Rest of SAO Preclinical Imaging Market Outlook, by Application, 2020-2033
6.4.18. Rest of SAO Preclinical Imaging Market Outlook, by End-User, 2020-2033
6.5. BPS Analysis/Market Attractiveness Analysis
7. Latin America Preclinical Imaging Market Outlook, 2020 - 2033
7.1. Latin America Preclinical Imaging Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
7.1.1. Modality
7.1.2. Reagent
7.1.3. Reagent
7.2. Latin America Preclinical Imaging Market Outlook, by Application, Value (US$ Bn), 2020-2033
7.2.1. Drug Discovery & Development
7.2.2. Toxicology & Pharmacokinetics Studies
7.2.3. Basic & Translational Research
7.2.4. Basic & Translational Research
7.2.5. Biomarker & Imaging Agent Validation
7.2.6. Others
7.3. Latin America Preclinical Imaging Market Outlook, by End-User, Value (US$ Bn), 2020-2033
7.3.1. Pharma and Biotech Companies
7.3.2. Contract Research Organizations (CROs)
7.3.3. Academic and Research Institutes
7.3.4. Others
7.4. Latin America Preclinical Imaging Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.4.1. Brazil Preclinical Imaging Market Outlook, by Product Type, 2020-2033
7.4.2. Brazil Preclinical Imaging Market Outlook, by Application, 2020-2033
7.4.3. Brazil Preclinical Imaging Market Outlook, by End-User, 2020-2033
7.4.4. Mexico Preclinical Imaging Market Outlook, by Product Type, 2020-2033
7.4.5. Mexico Preclinical Imaging Market Outlook, by Application, 2020-2033
7.4.6. Mexico Preclinical Imaging Market Outlook, by End-User, 2020-2033
7.4.7. Argentina Preclinical Imaging Market Outlook, by Product Type, 2020-2033
7.4.8. Argentina Preclinical Imaging Market Outlook, by Application, 2020-2033
7.4.9. Argentina Preclinical Imaging Market Outlook, by End-User, 2020-2033
7.4.10. Rest of LATAM Preclinical Imaging Market Outlook, by Product Type, 2020-2033
7.4.11. Rest of LATAM Preclinical Imaging Market Outlook, by Application, 2020-2033
7.4.12. Rest of LATAM Preclinical Imaging Market Outlook, by End-User, 2020-2033
7.5. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Preclinical Imaging Market Outlook, 2020 - 2033
8.1. Middle East & Africa Preclinical Imaging Market Outlook, by Product Type, Value (US$ Bn), 2020-2033
8.1.1. Modality
8.1.2. Reagent
8.1.3. Reagent
8.2. Middle East & Africa Preclinical Imaging Market Outlook, by Application, Value (US$ Bn), 2020-2033
8.2.1. Drug Discovery & Development
8.2.2. Toxicology & Pharmacokinetics Studies
8.2.3. Basic & Translational Research
8.2.4. Basic & Translational Research
8.2.5. Biomarker & Imaging Agent Validation
8.2.6. Others
8.3. Middle East & Africa Preclinical Imaging Market Outlook, by End-User, Value (US$ Bn), 2020-2033
8.3.1. Pharma and Biotech Companies
8.3.2. Contract Research Organizations (CROs)
8.3.3. Academic and Research Institutes
8.3.4. Others
8.4. Middle East & Africa Preclinical Imaging Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.4.1. GCC Preclinical Imaging Market Outlook, by Product Type, 2020-2033
8.4.2. GCC Preclinical Imaging Market Outlook, by Application, 2020-2033
8.4.3. GCC Preclinical Imaging Market Outlook, by End-User, 2020-2033
8.4.4. South Africa Preclinical Imaging Market Outlook, by Product Type, 2020-2033
8.4.5. South Africa Preclinical Imaging Market Outlook, by Application, 2020-2033
8.4.6. South Africa Preclinical Imaging Market Outlook, by End-User, 2020-2033
8.4.7. Egypt Preclinical Imaging Market Outlook, by Product Type, 2020-2033
8.4.8. Egypt Preclinical Imaging Market Outlook, by Application, 2020-2033
8.4.9. Egypt Preclinical Imaging Market Outlook, by End-User, 2020-2033
8.4.10. Nigeria Preclinical Imaging Market Outlook, by Product Type, 2020-2033
8.4.11. Nigeria Preclinical Imaging Market Outlook, by Application, 2020-2033
8.4.12. Nigeria Preclinical Imaging Market Outlook, by End-User, 2020-2033
8.4.13. Rest of Middle East Preclinical Imaging Market Outlook, by Product Type, 2020-2033
8.4.14. Rest of Middle East Preclinical Imaging Market Outlook, by Application, 2020-2033
8.4.15. Rest of Middle East Preclinical Imaging Market Outlook, by End-User, 2020-2033
8.5. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Bruker Corporation
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Cubresa Inc.
9.4.3. Siemens Healthineers
9.4.4. Revvity (formerly PerkinElmer, Inc.)
9.4.5. MR Solutions
9.4.6. Mediso Ltd.
9.4.7. Rigaku (MILabs B.V.)
9.4.8. Aspect Imaging
9.4.9. TriFoil Imaging
9.4.10. FUJIFILM VisualSonics
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations